Covestor’s Immunome IMNM Stock Holding History

Covestor’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1K	Buy	26 +18	+225%	+$385	﹤0.01%	2196
2026 Q1	$0	Buy	+8	New	+$178	﹤0.01%	2505

Other funds holding IMNM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Covestor's IMNM Position: Q2 2026 in Review

Covestor increased its Immunome (IMNM) stake by 225% in Q2 2026, buying an estimated $385 and bringing the position to 26 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2196.

Covestor first reported a position in IMNM in Q1 2026 and has held it in 2 quarters since. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

Covestor held 26 shares of Immunome worth $1K as of Q2 2026.
Covestor bought 18 Immunome shares in Q2 2026, an estimated $385.
Immunome made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2196 holding.
Covestor first reported a position in Immunome in Q1 2026 and has held it in 2 quarters since.
202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.